| Wendell Weller Weed, MD | |
|
3256 N North Hills Blvd, Fayetteville, AR 72703 | |
| (479) 442-4617 | |
| (479) 442-6544 |
| Full Name | Wendell Weller Weed |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 3256 N North Hills Blvd, Fayetteville, Arkansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932154606 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | C6175 (Arkansas) | Primary |
| Entity Name | Northhills Dermatology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306061031 PECOS PAC ID: 0547440612 Enrollment ID: O20110207000299 |
News Archive
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
Leading industrial technology specialist Tracerco, part of the Johnson Matthey group, has added to its range of award winning radiation monitors with a family of Personal Electronic Dosimeters (PEDs), providing a solution for every radiation monitoring need.
CID s.r.l., a European company leader in interventional medicine, will update interventional cardiologists on the status of their revolutionary drug eluting stent technology during The Drug Eluting Stent (DES) Summit at TCT 2010, Washington, DC on Wednesday, September 22, 2010. The lecture, entitled "Status of the CID Cre8 polymer-free DES program", will be delivered by Alexandre Abizaid, MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo Brazil, and will be part of the session "The Next Generation DES, Polymer-Free".
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wendell Weller Weed, MD 3256 N North Hills Blvd, Fayetteville, AR 72703 Ph: (479) 442-4617 | Wendell Weller Weed, MD 3256 N North Hills Blvd, Fayetteville, AR 72703 Ph: (479) 442-4617 |
News Archive
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
Leading industrial technology specialist Tracerco, part of the Johnson Matthey group, has added to its range of award winning radiation monitors with a family of Personal Electronic Dosimeters (PEDs), providing a solution for every radiation monitoring need.
CID s.r.l., a European company leader in interventional medicine, will update interventional cardiologists on the status of their revolutionary drug eluting stent technology during The Drug Eluting Stent (DES) Summit at TCT 2010, Washington, DC on Wednesday, September 22, 2010. The lecture, entitled "Status of the CID Cre8 polymer-free DES program", will be delivered by Alexandre Abizaid, MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo Brazil, and will be part of the session "The Next Generation DES, Polymer-Free".
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.
› Verified 9 days ago
Dr. Scott M Jackson, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4375 N Vantage Dr Ste 305, Fayetteville, AR 72703 Phone: 479-273-7006 | |
Dr. Robert D Brown, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4375 N. Vantage Drive, Suite 305, Fayetteville, AR 72703 Phone: 479-443-5100 Fax: 479-443-5117 | |
Mark Franklin Naylor, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1444 E Stearns St Ste 11, Fayetteville, AR 72703 Phone: 479-718-7546 Fax: 479-966-4979 | |
Christopher P Schach, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4375 N. Vantage Dr., Suite 305, Fayetteville, AR 72703 Phone: 479-443-5100 Fax: 479-443-5117 | |
Dr. Jamie Langenhan Abbott, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4375 N Vantage Dr Ste 305, Fayetteville, AR 72703 Phone: 479-443-5100 Fax: 479-443-5117 | |
Dr. Lance B. Henry, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1444 E Stearns St, Suite 11, Fayetteville, AR 72703 Phone: 479-718-7546 Fax: 479-966-4979 | |
Eric J Stewart, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4375 N. Vantage Dr., Suite 305, Fayetteville, AR 72703 Phone: 479-443-5100 Fax: 479-443-5117 |